10q22.3q23.2 recurrent region (includes BMPR1A)

  • 3
    Haplo
    Score
  • 1
    Triplo
    Score

Region Facts

Region Name
10q22.3q23.2 recurrent region (includes BMPR1A)
Cytoband
10q22.3-q23.2
Genomic Coordinates
GRCh37/hg19 chr10:81682843-88739388 NCBI Ensembl UCSC
GRCh38/hg38 chr10:79923087-86979631 NCBI Ensembl UCSC

Dosage Sensitivity Summary (Region)

Dosage ID:
ISCA-37424
Curation Status:
Complete
Issue Type:
Dosage Curation - Region
Description:
The 10q22.3q23.2 region contains a cluster of low copy repeats that mediate recurrent copy number changes through non-allelic homologous recombination. This review refers to CNVs involving recurrent breakpoint regions, which are sometimes referred to as regions 3 and 4 in the literature. Note that genes used as landmarks are not necessarily causative of the phenotype(s) associated with the region.
Haploinsufficiency:
Sufficient Evidence for Haploinsufficiency (3)
Triplosensitivity:
Little Evidence for Triplosensitivity (1)
Last Evaluated:
05/15/2023

Haploinsufficiency (HI) Score Details

HI Score:
3
HI Evidence Strength:
Sufficient Evidence for Haploinsufficiency (Disclaimer)
HI Evidence:
  • PUBMED: 31561016
    Lecoquierre et al. (2020) reported a novel case and reviewed the literature of 15 prior families and 20 DECIPHER database patients (12 with phenotypic information) with the recurrent 10q22.3q23.2 deletion. Consistent reported features amongst these individuals included developmental delay/intellectual disability, delayed language, behavioral abnormalities, heart defects, and dysmorphic features. Of the novel and previously published cases, inheritance was de novo for most (10/16), familial (dominant) in 1, maternal in 1, and unknown for 4 patients. The case report involving a 25-year-old adult patient was notable for the presence of BMPR1A-associated tumors, severe juvenile polyposis syndrome and gastric adenocarcinoma, as this phenotype was not previously reported in patients with deletions isolated to the recurrent 10q22.3q23.2 region (i.e. excluding co-deletion of the gene PTEN, which resides outside of and distal to LCR-4). Due to the early age of ascertainment for most previously reported 10q22.3q23.2 recurrent deletion patients (11 patients ascertained at <5 years of age), the authors noted the absence of these reported phenotypes, JPS and/or GI tract adenocarcinomas, may not preclude a risk for development in young adulthood, and recommended early surveillance for these tumors.
  • PUBMED: 24550761
    Petrova et al. (2014) reported a novel case and reviewed the literature of 13 prior patients with recurrent 10q22.3q23.2 deletions. Clinical findings in common across these 14 patients typically included developmental delay (particularly in speech) and craniofacial dysmorphisms (particularly hypertelorism, up- or downslanting palpebral fissures and flat nasal bridge), and variably included palatal anomalies, congenital heart defects, and club foot. Inheritance was de novo for most (11/14), maternal for 2 and unknown for 1 patient. The authors noted none of these patients had juvenile polyposis syndrome (JPS) which was thought to require co-deletion of BMPR1A, which resides within the recurrent region, and PTEN, which is just outside of (distal to) LCR-4, although 11/14 were age 5 years or younger at the time of ascertainment.
  • PUBMED: 28588438
    Molck et al. (2017) reported a novel case and summarized clinical findings of 14 prior patients from the literature with 10q22.3q23.2 deletions. Their proband was also found to carry a 189 kb deletion within 16q12.1, which the authors noted could not be excluded as contributing to their phenotype, though reported features overlapped those of previously reported patients.
  • PUBMED: 21248748
    van Bon et al. (2011) summarized clinical findings for 5 patients with recurrent 10q22.3q23.2 deletions and 1 patient with a unique overlapping deletion identified by routine clinical microarray testing. Common phenotypic features among these 5 patients included developmental delay, speech delay, and dysmorphic features (such as hypertelorism and low-set ears). Additional variable findings included cardiac anomalies, brain anomalies, hand abnormalities and congenital breast aplasia. One patient had an additional de novo duplication in 2q36 (significance not disclosed) and another patient had a 47,XYY karyotype. The 10q22.3q23.3 deletion was apparently de novo in 3/5 cases, inherited from a mother who underwent special schooling in one case, and of unknown inheritance in the last case.
  • PUBMED: 23057600
    Fernandez-Rozadilla et al. (2012) performed a search for rare copy number variants detected by microarray analysis in a cohort of 32 patients with familial colorectal cancer type X, juvenile polyposis, or hereditary mixed polyposis syndromes. The recurrent 10q22.3q23.2 deletion was reported in a patient with a history of mild intellectual disability, an unspecified heart condition, and apparently sporadic synchronous colorectal adenocarcinomas at age 49 years. The family history was negative for colorectal cancer.
HI Evidence Comments:
The recurrent 10q22.3q23.2 deletion has been reported in 15 individuals to date and is associated with a variable clinical phenotype that typically includes developmental delay (particularly motor and speech delay), mild dysmorphic features, heart defects, and hand/foot anomalies. Less common findings include macrocephaly, cerebellar anomalies, breast aplasia, hypotonia, autism, and joint hyperextensibility. The reported deletions are typically de novo, although inheritance, sometimes from a mildly affected parent, has been documented. Case-control comparison studies have shown enrichment of this deletion in clinical populations. This region contains the gene BMPR1A (see linked gene review). BMPR1A loss-of-function is associated with juvenile polyposis syndrome (JPS). Although JPS has not been observed in all individuals with 10q22.3q23.2 deletions including BMPR1A, this recurrent deletion is rare, and many of the carriers reported in the literature are below the age at which JPS typically presents; most recent guidance suggests JPS surveillance for deletion carriers although penetrance is unknown at this time. Taken together, the haploinsufficiency score is 3. Additional relevant literature is summarized below: Case-Control Studies: PMID: 25217958 Coe et al. (2014) performed a large-scale case-control comparison study of the relative prevalence of CNVs in children with developmental delay/intellectual disability, multiple congenital anomalies, and other developmental phenotypes compared to controls. Deletions of the recurrent 10q22.3q23.2 region were observed in 11/29,085 cases versus 0/19,584 controls (p=0.0035; LR: Inf, 95% CI: 2.21 to Inf), demonstrating enrichment of this CNV in the clinical population. See also Cooper et al. (2011) PMID 21841781, which uses an overlapping (older) dataset. Additional reports: 17436248, 20345475, 20714122, 21808946, 33009833

Triplosensitivity (TS) Score Details

TS Score:
1
TS Evidence Strength:
Little Evidence for Triplosensitivity (Disclaimer)
TS Published Evidence:
  • PUBMED: 21248748
    van Bon et al. (2011) summarized clinical findings for 3 patients with recurrent 10q22.3q23.2 duplications and 3 patients with unique overlapping duplications identified by routine clinical microarray testing. The recurrent duplication was identified in a sibling pair (patients 10-11) and an unrelated individual (patient 12). Common phenotypic features among these 3 patients included developmental delay and dysmorphic features (deep set eyes, hypertelorism, and thin upper lip). The duplication for patients 10-11 was inherited from an apparently unaffected mother. For patient 12, the duplication was de novo; this patient also had a de novo 16p13.11 (BP2-BP3) (includes MYH11) deletion which may have contributed to the clinical presentation.
  • PUBMED: 26383923
    Tang et al. (2015) reported a patient with a de novo recurrent 10q22.3q23.2 duplication identified by both chromosome analysis and SNP microarray. Clinical features included severe microcephaly (<3rd percentile), growth delays, mild intellectual disability, speech delay, cardiac defect (ASD), multiple congenital anomalies, and distinctive facial features (smooth philtrum, large wide spaced teeth, thin upper lip, mild auricle deformity, low-set ears, highly arched eyebrows).
  • PUBMED: 22043167
    Dasouki et al. (2011) reported an adult female patient with the recurrent 10q22.3q23.2 duplication. Her clinical features included early onset obesity, idiopathic urticaria, endometriosis, and kidney anomalies. Maternal inheritance was excluded, and a paternal sample was not available for testing.
TS Evidence Comments:
Evidence in support of the pathogenicity of the recurrent 10q22.3q23.2 duplication is limited at this time. Duplications of this region are rare in the literature, with 5 independent cases reported across 3 studies. Among affected carriers, clinical findings are mostly nonspecific, including developmental and speech delay, dysmorphic features, and other variable findings. Due to the limited number of reported cases with variable inheritance and lack of parental phenotype information, inheritance and penetrance are not well-understood. Of note, the recurrent 10q22.3q23.2 duplication appears to be absent in individuals in the general population from studies of natural genomic variation. Case-control studies, where performed, have a limited overall number of cases, therefore enrichment of this duplication has not been established in the clinical population. Therefore, the triplosensitivity score is 1. Additional literature is summarized below: Case-Control Studies PMID: 25217958 Coe et al. (2014) performed a large-scale case-control comparison study of the relative prevalence of CNVs in children with developmental delay/intellectual disability, multiple congenital anomalies, and other developmental phenotypes compared to controls. Duplications of the recurrent 10q22.3q23.2 region were observed in 4/29,085 cases versus 0/19,584 controls (p=0.1280; LR: Inf, 95% CI: 0.559 to Inf), with limited numbers and no evidence of enrichment of this CNV in the clinical population. See also Cooper et al. (2011) PMID 21841781, which uses an overlapping (older) dataset.

Genomic View

Select assembly: (NC_000010.10) ()